Arcoxia
etoricoxib
Treatment for OsteoarthritisMerck Provides Status Update on Ongoing Arcoxia Trials
WHITEHOUSE STATION, N.J., June 17, 2005 - As previously announced, on Oct. 29, 2004, Merck & Co., Inc. received an "approvable" letter from the U.S. Food and Drug Administration (FDA) for the company's New Drug Application (NDA) for Arcoxia (etoricoxib). The FDA informed Merck in that letter that before approval of the NDA can be issued, additional safety and efficacy data for Arcoxia are required. These data will include data from ongoing clinical trials for Arcoxia, known as MEDAL and EDGE II. These trials are being monitored by a Data Safety Monitoring Board (DSMB) responsible for the ongoing safety of the trials. The DSMB met recently and recommended that the studies continue as planned. Merck remains blinded to the clinical data from these trials.
About Merck
Merck & Co., Inc. is a global research-driven pharmaceutical
company dedicated to putting patients first. Established in 1891,
Merck discovers, develops, manufactures and markets vaccines and
medicines in more than 20 therapeutic categories. The company
devotes extensive efforts to increase access to medicines through
far-reaching programs that not only donate Merck medicines but help
deliver them to the people who need them. Merck also publishes
unbiased health information as a not-for-profit service.
For more information, please visit the Merck website.
Related Articles:
Merck Receives Non Approvable Letter from FDA for Arcoxia (etoricoxib) - April 27, 2007
Public Citizen: FDA Should Not Approve "Offspring of Vioxx" Painkiller - April 13, 2007
FDA Advisory Committee Recommends Against Approval for Merck's NDA for Arcoxia (etoricoxib) - April 12, 2007
Statement by Merck & Co., Inc. Regarding FDA Arthritis Drugs Advisory Committee Meeting on Arcoxia (etoricoxib) - April 11, 2007
Arthritis Foundation Chief Public Health Officer Testifies at FDA Hearing on Arcoxia - April 9, 2007
Merck Responds to FDA-Issued Approvable Letters for Arcoxia (etoricoxib) - November 10, 2006
Merck Receives ’Approvable’ Letter for Arcoxia - October 29, 2004
New Drug Applications Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
